The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Crush techniques for percutaneous coronary intervention of bifurcation lesions

DOI: 10.4244/EIJ-D-21-00690

1. Division of Cardiology, VCU Health Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA; 2. Cardiology Department, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom; 3. Department of Cardiology, Ascension St. John Hospital, Detroit, MI, USA; 4. PCI Cardiology Group, Bayamon Heart and Lung Institute, Bayamon, Puerto Rico, USA; 5. PCI Cardiology Group, Manatí Cardiovascular Interventional Institute, Manatí, Puerto Rico, USA; 6. Santa Casa de Misericórdia de Maceió, Maceió, AL, Brasil; 7. Prairie Cardiovascular Consultants, Springfield, IL, USA; 8. New York University Grossman School of Medicine, New York, NY, USA

Percutaneous coronary intervention (PCI) of coronary artery bifurcation lesions entails technical challenges and carries a higher risk of adverse events on follow-up, driven by repeat revascularisation and stent thrombosis. While most bifurcations can be tackled with a provisional (single-stent) approach, more complex lesions involving both branches (true bifurcation lesions) require a two-stent approach. In the latter context, several techniques have been proposed. Among them, the crush technique has dramatically evolved in recent years, and its more recent iterations have been shown to provide excellent and durable results, both for left main and non-left main bifurcations. The aim of the present work is to discuss the technical aspects and outcomes of the variants of the crush technique from the first description in the early 2000s to the present day.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
A prospective, multicentre first-in-man study of the polymer-free ultrathin-strut BIOrapid stent (BIOVITESSE)